Activation of myosin in HeLa cells causes redistribution of focal adhesions and F-actin from cell center to cell periphery.
Activation of actomyosin II by phosphorylation of its regulatory light chain is one of the main factors involved in the regulation of cytoskeletal dynamics. Phosphorylation of myosin regulatory light chain may be mediated directly and indirectly by several kinases including myosin light chain kinase (MLCK) and kinases activated by small GTP-binding proteins. Most of the myosin kinases, including PAK, can also interact with other proteins through binding sites located outside of their catalytic domains. In an attempt to study the effects due only to phosphorylation of myosin light chain, we expressed the constitutively active catalytic domain of ameba PAK in HeLa cells. The catalytic domain phosphorylates myosin light chain in vitro with high specific activity but has none of the sequences that target mammalian PAK to other proteins and membranes. Expression of the catalytic domain caused disassembly of focal adhesions and stress fibers in the cell center and accumulation of focal adhesions and F-actin at the cell periphery. There was a twofold increase in the phosphorylation level of endogenous myosin light chain and changes in cell shape consistent with enhanced cell contractility. The phenotype was independent of MLCK, ROCK, MEK, Rac, and Rho activities but was abolished by blebbistatin, a specific inhibitor of myosin II activity. Our data are consistent with myosin being directly phosphorylated by the expressed catalytic domain of ameba PAK with the induced phenotype resulting from cell retraction driven by contraction of peripheral actomyosin. The phenotype induced by expression of the catalytic domain is reminiscent of that caused by expression of active mammalian PAK, suggesting that myosin phosphorylation may play an important role in PAK-induced cytoskeletal changes. The catalytic domain of ameba PAK may be a useful tool for studying the effects of myosin light chain phosphorylation in other cells.
Szczepanowska
Joanna
J
Laboratory of Cell Biology, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA.
Korn
Edward D
ED
Brzeska
Hanna
H
D000199:Actins / Q000378:metabolism*; D000205:Actomyosin / Q000378:metabolism; D000656:Amoeba / Q000201:enzymology / Q000235:genetics; D000818:Animals; D020134:Catalytic Domain; D002467:Cell Nucleus / Q000378:metabolism / Q000648:ultrastructure; D048749:Cytokinesis / Q000502:physiology; D022001:Focal Adhesions / Q000201:enzymology / Q000378:metabolism*; D006367:HeLa Cells; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology; D006801:Humans; D018994:Myosin Light Chains / Q000378:metabolism; D024462:Myosin Type II / Q000037:antagonists & inhibitors / Q000378:metabolism; D009218:Myosins / Q000378:metabolism*; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D022502:Stress Fibers / Q000378:metabolism; D014162:Transfection; D016596:Vinculin / Q000378:metabolism; D054462:p21-Activated Kinases
D000199:Actins; D006576:Heterocyclic Compounds, 4 or More Rings; D018994:Myosin Light Chains; D016596:Vinculin; C472645:blebbistatin; D000205:Actomyosin; C515907:PAK2 protein, human; D017346:Protein Serine-Threonine Kinases; D054462:p21-Activated Kinases; D024462:Myosin Type II; D009218:Myosins